Kamegai J, Wakabayashi I, Miyamoto K, Unterman T G, Kineman R D, Frohman L A
Department of Medicine, Section of Endocrinology and Metabolism, University of Illinois at Chicago, Ill., 60612, USA.
Neuroendocrinology. 1998 Nov;68(5):312-8. doi: 10.1159/000054379.
Growth hormone secretagogues (GHSs) are synthetic peptidyl and nonpeptidyl compounds that are believed to stimulate the release of GH by a direct effect on the pituitary somatotrope and by stimulation of growth hormone-releasing hormone (GHRH) release and the suppression of somatostatin (SRIH) tone. Recently, the receptor for these pharmacologic agents was cloned and its expression localized to the pituitary and hypothalamus. The elucidation of an unique GHS receptor (GHS-R) suggests there is a yet to be identified endogenous ligand which could exert an important role in regulation of GH secretion. It is clearly established that GH acts to regulate its own production by feeding back at the level of the hypothalamus to downregulate GHRH and upregulate SRIH synthesis and by induction of IGF-I, which acts at the pituitary to block somatotrope responsiveness to GHRH. If the endogenous GHS/GHS-R signaling system is important in regulating GH release, it might be reasoned that changes in circulating GH concentrations would also directly or indirectly (via generation of IGF-I) modify GHS-R production. To test this hypothesis we used RT-PCR to examined pituitary and hypothalamic GHS-R mRNA levels in the spontaneous dwarf rat (SDR), an animal model characterized by the absence of GH due to a point mutation in the GH gene. In the absence of GH feedback regulation, SDR pituitary GHS-R mRNA levels were 385 +/- 61% greater (p < 0.01) than those observed in normal controls while SDR hypothalamic GHS-R mRNA levels were not significantly different from those in normal rats. Three-day subcutaneous infusion of rat GH by osmotic pump reduced SDR pituitary GHS-R mRNA levels to 55 +/- 9% of vehicle-treated controls (p < 0.05) but did not significantly alter hypothalamic GHS-R mRNA levels. To test if the changes in GHS-R mRNA levels observed following GH treatment were due to elevation of circulating IGF-I concentrations, SDRs were infused with recombinant human IGF-I. Replacement of IGF-I did not significantly alter either pituitary or hypothalamic GHS-R mRNA levels, indicating that GH acts independent of circulating IGF-I to regulate pituitary GHS-R expression in the SDR model.
生长激素促分泌素(GHSs)是合成的肽类和非肽类化合物,据信它们通过直接作用于垂体生长激素细胞、刺激生长激素释放激素(GHRH)释放以及抑制生长抑素(SRIH)张力来刺激生长激素(GH)的释放。最近,这些药物的受体被克隆出来,其表达定位于垂体和下丘脑。独特的生长激素促分泌素受体(GHS-R)的阐明表明,存在一种尚未被鉴定的内源性配体,它可能在生长激素分泌的调节中发挥重要作用。很明显,生长激素通过在下丘脑水平进行反馈以下调GHRH并上调SRIH合成,以及通过诱导胰岛素样生长因子-I(IGF-I)来调节其自身的产生,IGF-I作用于垂体以阻断生长激素细胞对GHRH的反应。如果内源性GHS/GHS-R信号系统在调节生长激素释放中很重要,那么可以推断循环中生长激素浓度的变化也会直接或间接(通过IGF-I的产生)改变GHS-R的产生。为了验证这一假设,我们使用逆转录聚合酶链反应(RT-PCR)检测了自发性侏儒大鼠(SDR)垂体和下丘脑的GHS-R mRNA水平,SDR是一种动物模型,其特征是由于生长激素基因的点突变而缺乏生长激素。在没有生长激素反馈调节的情况下,SDR垂体GHS-R mRNA水平比正常对照组高385±61%(p<0.01),而SDR下丘脑GHS-R mRNA水平与正常大鼠无显著差异。通过渗透泵皮下注射大鼠生长激素3天,使SDR垂体GHS-R mRNA水平降至载体处理对照组的55±9%(p<0.05),但未显著改变下丘脑GHS-R mRNA水平。为了测试生长激素治疗后观察到的GHS-R mRNA水平变化是否是由于循环中IGF-I浓度升高所致,给SDR注射重组人IGF-I。补充IGF-I并未显著改变垂体或下丘脑的GHS-R mRNA水平,表明在SDR模型中,生长激素独立于循环中的IGF-I发挥作用来调节垂体GHS-R的表达。